Zacks: Brokerages Anticipate Anixa Biosciences, Inc. (NASDAQ:ANIX) Will Announce Earnings of -$0.11 Per Share


Share on StockTwits

Equities research analysts predict that Anixa Biosciences, Inc. (NASDAQ:ANIX) will announce earnings of ($0.11) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Anixa Biosciences’ earnings. Anixa Biosciences reported earnings per share of ($0.13) in the same quarter last year, which suggests a positive year-over-year growth rate of 15.4%. The business is expected to announce its next quarterly earnings report on Monday, March 8th.

On average, analysts expect that Anixa Biosciences will report full year earnings of ($0.51) per share for the current year, with EPS estimates ranging from ($0.53) to ($0.49). For the next financial year, analysts anticipate that the firm will post earnings of ($0.60) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Anixa Biosciences.

A number of brokerages have weighed in on ANIX. Aegis restated a “buy” rating on shares of Anixa Biosciences in a report on Monday, February 15th. Zacks Investment Research lowered Anixa Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, January 14th.

ANIX stock traded down $0.33 during midday trading on Tuesday, reaching $4.60. The stock had a trading volume of 8,985 shares, compared to its average volume of 395,993. The company’s fifty day simple moving average is $4.40 and its 200 day simple moving average is $2.99. The company has a market cap of $119.95 million, a price-to-earnings ratio of -10.00 and a beta of 1.58. Anixa Biosciences has a 52-week low of $1.33 and a 52-week high of $5.63.

In other Anixa Biosciences news, CEO Amit Kumar bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, January 29th. The stock was purchased at an average price of $3.73 per share, for a total transaction of $37,300.00. Following the completion of the purchase, the chief executive officer now directly owns 272,000 shares in the company, valued at $1,014,560. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 23.30% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in shares of Anixa Biosciences by 8.0% in the fourth quarter. BlackRock Inc. now owns 93,942 shares of the company’s stock valued at $289,000 after purchasing an additional 6,964 shares during the period. B. Riley Wealth Management Inc. acquired a new position in Anixa Biosciences during the fourth quarter worth $37,000. Bank of New York Mellon Corp grew its holdings in Anixa Biosciences by 32.0% in the fourth quarter. Bank of New York Mellon Corp now owns 51,969 shares of the company’s stock valued at $160,000 after purchasing an additional 12,588 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Anixa Biosciences in the third quarter valued at $45,000. 7.68% of the stock is currently owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus.

Recommended Story: What are different types of coverage ratios?

Get a free copy of the Zacks research report on Anixa Biosciences (ANIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Anixa Biosciences (NASDAQ:ANIX)

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.